Dr. Grant talks to a young patient at bedside

Duke Neurosurgery

Duke represents excellence in neurosurgical care, research, and education. A team of highly skilled neurosurgeons provide comprehensive care for patients in all sub-specialties. Clinicians embrace a multidisciplinary, team-based approach to care, with a commitment to the very best patient outcomes. Duke Neurosurgery excels at translational research, moving innovations rapidly from bench to bedside.
Dr. Goodwin with a patient

Duke Spine Center
Dr. Chandramohan in her lab

Preston Robert Tisch Brain Tumor Center
Leadership of the Duke Center for Brain and Spine Metastasis, left to right: Carey Anders, MD; Anoop Patel, MD; Rory Goodwin, MD, PhD; Peter Fecci, MD, PhD; John Kirkpatrick, MD, PhD; and Betsy Fricklas, PA-C, MMSc.

Duke Center for Brain and Spine Metastasis

Highlights

A group of residents taking a selfie

Get to Know Our Residents

Meet the 21 members of our outstanding team of residents
Nanthia Suthana looks at VR scenes being shown to her study volunteer with her lab colleague.

Neurorestoration

Reimagining recovery from brain and spine injury and disease
10 Years 10 Milestones A Decade of Innovation and Impact

10 Years, 10 Milestones

Highlights of the first decade of Duke Neurosurgery

New in Duke Neurosurgery

Shruti Agashe, MD, MS; Derek Southwell, MD, PhD

Epileptic seizures are unpredictable, often occurring in clusters followed by seizure-free periods lasting weeks or months. Diagnosing and characterizing epilepsy depends on capturing these sporadic seizures during electroencephalography (EEG) monitoring.

Patrick Codd, MD, works with a robot in the lab.

When Dr. Patrick Codd was a neurosurgery medical resident, he treated a 2-year-old with a large brain tumor. The tumor had caused fluid build-up, and Codd needed to drill a hole into the child’s skull to relieve pressure.

Vidyalakshmi Chandramohan, PhD, MBA; Darell Bigner, MD, PhD; Annick Desjardins, MD

Researchers from Duke’s Preston Robert Tisch Brain Tumor Center have found that a therapy targeting the epidermal growth factor receptor (EGFR) can be safely delivered directly into recurrent glioblastomas and may improve patient

Kirit Singh, MD, PhD and Mustafa Khasraw, MD

Duke researchers are leading a phase I clinical trial to evaluate a new experimental treatment for glioblastoma, one of the most aggressive and deadly forms of

See all news